THER (Theralink Technologies) Scaled Net Operating Assets: -11.71 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Theralink Technologies Scaled Net Operating Assets?

Theralink Technologies THER -99.00% Scaled Net Operating Assets is -11.71 as of Dec. 2023.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Theralink Technologies's operating assets for the quarter that ended in Dec. 2023 was $1.76 Mil. Theralink Technologies's operating liabilities for the quarter that ended in Dec. 2023 was $35.15 Mil. Theralink Technologies's Total Assets for the quarter that ended in Sep. 2023 was $2.85 Mil. Therefore, Theralink Technologies's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -11.71.


Theralink Technologies Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Theralink Technologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralink Technologies Scaled Net Operating Assets Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.98 3.13 -0.56 0.11 -7.45

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.31 -13.87 -15.58 -11.22 -11.72

THER vs AXIM, ISCO, RMTG: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Theralink Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Scaled Net Operating Assets falls into.



Theralink Technologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Theralink Technologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Sep. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Sep. 2023 )
=(Operating Assets (A: Sep. 2023 )-Operating Liabilities (A: Sep. 2023 ))/Total Assets (A: Sep. 2022 )
=(1.852-21.203)/2.599
=-7.45

where

Operating Assets(A: Sep. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.85 - 0.998
=1.852

Operating Liabilities(A: Sep. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=40.965 - 1.131 - 18.631
=21.203

Theralink Technologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(1.76-35.147)/2.85
=-11.71

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1.784 - 0.024
=1.76

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=58.902 - 1.117 - 22.638
=35.147

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -11.71 mean?
Theralink Technologies (THER) has a Scaled Net Operating Assets of -11.71 as of Dec. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Theralink Technologies and its competitors.
Is Theralink Technologies' Scaled Net Operating Assets too high?
Theralink Technologies' current Scaled Net Operating Assets is -11.71.
How does Theralink Technologies' Scaled Net Operating Assets compare to AXIM and ISCO?
Theralink Technologies' Scaled Net Operating Assets of -11.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Theralink Technologies and its competitors. Theralink Technologies's current Scaled Net Operating Assets is -11.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralink Technologies stock overvalued right now?
Theralink Technologies (THER) has a current Scaled Net Operating Assets of -11.71. The current Scaled Net Operating Assets is -11.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Theralink Technologies (THER), the current Scaled Net Operating Assets is -11.71 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theralink Technologies Business Description

Address 15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.